This week’s China healthcare roundup from PharmaBoardroom content partner Selesta highlights Kite Pharma’s US$1.64B in vivo CAR-T deal with Pregene, Xuanzhu Biopharma’s HKEX debut with a 172% grey market premium, Hansoh’s US$1.53B CDH17 ADC licensing to Roche, and Leads Biolabs’ US$1B autoimmune drug deal with Dianthus. Biokin secured a record US$250M milestone from BMS, while I-Mab rebrands as NovaBridge and plans an HKEX listing. Key clinical updates include Kelun’s ADC advances, Hemay’s PDE4 inhibitor approval, CSPC’s GLP-1 NDA, Qilu’s PROTAC progress, and RemeGen’s IgA nephropathy NDA.
